No Data
GF Securities: Stable coal prices start a new thermal power trilogy
Currently, thermal power is in a “moment of disagreement” from cycle to value. It is recommended to pay attention to the industry trend where coal prices are stabilizing, and pay more attention to the verification and pricing opportunities of thermal power utilities under increased ROE stability.
Zhitong Finance23:51 ET
[Special Offer V] Ye Shangzhi: Hong Kong Stock A Shares Will Resonate Together
Jinwu Financial News | On April 26, driven by continued capital inflows, Hong Kong stocks rose for the fifth day and tested to the first target of the 250-day line (latest report of 17,717 points). The Hang Seng Index rose by nearly 370 points and closed at the level of 17,600 points, while market turnover further increased to close to 160 billion yuan, the largest daily turnover since this year, and the highest in nine months. It is worth noting that not only Hong Kong stocks, but A-shares are also showing signs of becoming the current target of foreign capital inflows. The Shanghai and Shenzhen Stock Connect recorded a net inflow of over 22 billion yuan on Friday, which hit a new high since its opening. It is estimated that Hong Kong stocks have become targets
金吾財訊23:24 ET
CICC: Maintaining China Resources Building Materials Technology's (01313) “Outperform the Industry” Rating Target Price of HK$1.93
The Zhitong Finance App learned that CICC released a research report stating that while maintaining China Resources Building Materials Technology's (01313) “outperforming the industry” rating, the 2024/25E net profit of 676 million yuan/804 million yuan remained unchanged, with a target price of HK$193 million. The company announced 1Q24 results: revenue of 4.79 billion yuan, -5.6% year-on-year; net profit to mother of -0.28.9 million yuan, compared to -0.30 billion yuan for the same period in 1Q23. The company's 1Q24 performance is basically in line with this forecast. According to the report, the company's leading position in the region has been consolidated, and the aggregate business has entered a period of rapid growth. The company proposed “grab shares, stick to the bottom line,
Zhitong Finance21:11 ET
China Resources Pharmaceutical (03320.HK): Jiangzhong Pharmaceutical's net profit of 267 million yuan in the first quarter increased 9.99% year-on-year
Gelonghui, April 29丨China Resources Pharmaceutical (03320.HK) announced that Jiangzhong Pharmaceutical (600750.SH) achieved operating income of 1,227 billion yuan in the first quarter of 2024, down 8.74% year on year; net profit attributable to shareholders of listed companies (Jiangzhong Pharmaceutical) was 267 million yuan, up 9.99% year on year; net profit attributable to shareholders of listed companies (Jiangzhong Pharmaceutical) after deducting non-recurring profit and loss was 264 million yuan, up 16.64% year on year.
Gelonghui Finance20:11 ET
華潤醫藥:公告江中藥業截至2024年3月31日止三個月的未經審核財務業績
Futu News20:01 ET · Announcements
Huatai Securities: Chengdu's release of a new real estate policy is expected to stimulate market demand
In the long run, an increase in high-quality supply is expected to increase the market competitiveness of new homes in the next 1-2 years.
Zhitong Finance19:48 ET